Jump to content

Arbaclofen placarbil

From Wikipedia, the free encyclopedia
(Redirected from Arbaclofen)
Arbaclofen placarbil
Clinical data
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
  • (3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.221.150 Edit this at Wikidata
Chemical and physical data
FormulaC19H26ClNO6
Molar mass399.87 g·mol−1
3D model (JSmol)
  • CC(C)C(=O)O[C@@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)C(C)C
  • InChI=1S/C19H26ClNO6/c1-11(2)17(24)26-18(12(3)4)27-19(25)21-10-14(9-16(22)23)13-5-7-15(20)8-6-13/h5-8,11-12,14,18H,9-10H2,1-4H3,(H,21,25)(H,22,23)/t14-,18-/m0/s1
  • Key:JXTAALBWJQJLGN-KSSFIOAISA-N

Arbaclofen placarbil (/ɑːrˈbæklfɛn pləˈkɑːrbɪl/ ar-BAK-loh-fen plə-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.[1]

It is being developed as an addiction medicine to treat alcoholism. [2] It is also studied as a potential therapeutic for some autistic subjects.[3]

See also

[edit]

References

[edit]
  1. ^ "XenoPort Reports Top-Line Results of Phase 3 Trial of Arbaclofen Placarbil for Spasticity in Multiple Sclerosis Patients". XenoPort, Inc. May 20, 2013. Archived from the original on 2013-12-02. Retrieved 2013-06-03.
  2. ^ Anderson E (3 July 2020). "Pill that replaces alcohol aims to end 'glass of wine' craving". The i newspaper. Associated Newspapers Limited.
  3. ^ Huang Q, Pereira AC, Velthuis H, Wong NM, Ellis CL, Ponteduro FM, et al. (January 2022). "GABAB receptor modulation of visual sensory processing in adults with and without autism spectrum disorder" (PDF). Science Translational Medicine. 14 (626): eabg7859. doi:10.1126/scitranslmed.abg7859. PMID 34985973. S2CID 245771626.